NASDAQ:AZRX - AzurRx BioPharma News Headlines

$1.08
+0.03 (+2.86 %)
(As of 07/22/2019 04:00 PM ET)
Today's Range
$1.01
Now: $1.08
$1.28
50-Day Range
$0.99
MA: $1.64
$2.2107
52-Week Range
$0.91
Now: $1.08
$3.75
Volume41,467 shs
Average Volume281,530 shs
Market Capitalization$22.74 million
P/E RatioN/A
Dividend YieldN/A
Beta2.24

Headlines

AzurRx BioPharma (NASDAQ AZRX) News Headlines

Source:
DateHeadline
 Brokerages Anticipate AzurRx BioPharma Inc (NASDAQ:AZRX) to Post -$0.22 Earnings Per Share Brokerages Anticipate AzurRx BioPharma Inc (NASDAQ:AZRX) to Post -$0.22 Earnings Per Share
www.americanbankingnews.com - July 21 at 12:09 AM
AzurRx BioPharma Announces Pricing of $5.0 Million Public Offering of Common StockAzurRx BioPharma Announces Pricing of $5.0 Million Public Offering of Common Stock
finance.yahoo.com - July 18 at 10:26 AM
AzurRx readies stock offering; shares down 4% after hoursAzurRx readies stock offering; shares down 4% after hours
seekingalpha.com - July 17 at 5:13 PM
AzurRx BioPharma Inc (NASDAQ:AZRX) Receives Average Recommendation of "Buy" from BrokeragesAzurRx BioPharma Inc (NASDAQ:AZRX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - July 14 at 6:53 AM
AZRX: Launch of Study for Cystic Fibrosis Patients With Severe EPIAZRX: Launch of Study for Cystic Fibrosis Patients With Severe EPI
finance.yahoo.com - July 10 at 5:23 PM
AzurRx initiates new mid-stage study of MS1819-SD in cystic fibrosis; shares up 12% after hoursAzurRx initiates new mid-stage study of MS1819-SD in cystic fibrosis; shares up 12% after hours
seekingalpha.com - July 8 at 5:30 PM
AzurRx BioPharma Announces Initiation of Phase 2 Clinical Study for MS1819-SD in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic InsufficiencyAzurRx BioPharma Announces Initiation of Phase 2 Clinical Study for MS1819-SD in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
finance.yahoo.com - July 8 at 5:30 PM
AzurRx BioPharma Announces R&D Update Call on Monday, July 8th at 4:30 PM ETAzurRx BioPharma Announces R&D Update Call on Monday, July 8th at 4:30 PM ET
finance.yahoo.com - July 8 at 5:30 PM
AzurRx BioPharma Inc (NASDAQ:AZRX) Sees Significant Increase in Short InterestAzurRx BioPharma Inc (NASDAQ:AZRX) Sees Significant Increase in Short Interest
www.americanbankingnews.com - June 30 at 1:09 AM
-$0.21 Earnings Per Share Expected for AzurRx BioPharma Inc (NASDAQ:AZRX) This Quarter-$0.21 Earnings Per Share Expected for AzurRx BioPharma Inc (NASDAQ:AZRX) This Quarter
www.americanbankingnews.com - June 28 at 6:27 AM
AzurRx BioPharma Announces Notice of Allowance of U.S. and Japan Patents Covering a MTAN Inhibitor for Treating H. Pylori Infections, the Primary Cause of Stomach UlcersAzurRx BioPharma Announces Notice of Allowance of U.S. and Japan Patents Covering a MTAN Inhibitor for Treating H. Pylori Infections, the Primary Cause of Stomach Ulcers
finance.yahoo.com - June 7 at 5:42 PM
How Many AzurRx BioPharma, Inc. (NASDAQ:AZRX) Shares Did Insiders Buy, In The Last Year?How Many AzurRx BioPharma, Inc. (NASDAQ:AZRX) Shares Did Insiders Buy, In The Last Year?
finance.yahoo.com - May 28 at 9:36 AM
AZRX: Secondary Endpoint Data Released for MS1819-SD in Chronic Pancreatitis PatientsAZRX: Secondary Endpoint Data Released for MS1819-SD in Chronic Pancreatitis Patients
finance.yahoo.com - May 23 at 6:13 PM
AzurRx BioPharma Reaches Enrollment Target for Phase II OPTION Clinical TrialAzurRx BioPharma Reaches Enrollment Target for Phase II OPTION Clinical Trial
finance.yahoo.com - May 23 at 9:38 AM
AzurRx down 9% on new MS1819 SD dataAzurRx down 9% on new MS1819 SD data
seekingalpha.com - May 21 at 6:15 PM
AzurRx BioPharma Presents Positive Secondary Endpoint Data in its Phase II MS1819-SD Chronic Pancreatitis Study at the 2019 Digestive Disease Week ConferenceAzurRx BioPharma Presents Positive Secondary Endpoint Data in its Phase II MS1819-SD Chronic Pancreatitis Study at the 2019 Digestive Disease Week Conference
finance.yahoo.com - May 20 at 4:54 PM
AzurRx BioPharma Exceeds 50% Enrollment Target for Phase II OPTION Clinical TrialAzurRx BioPharma Exceeds 50% Enrollment Target for Phase II OPTION Clinical Trial
finance.yahoo.com - April 23 at 9:39 AM
AZRX: CF Study Up and Enrolling; Target to $8AZRX: CF Study Up and Enrolling; Target to $8
finance.yahoo.com - April 11 at 10:59 AM
Expanded MS1819-SD Global Commercialization Rights Now Owned by AzurRx BioPharma along with Full Development RightsExpanded MS1819-SD Global Commercialization Rights Now Owned by AzurRx BioPharma along with Full Development Rights
finance.yahoo.com - April 2 at 12:03 PM
AzurRx BioPharma IncAzurRx BioPharma Inc
www.bloomberg.com - March 19 at 9:58 AM
AzurRx BioPharma, Inc. Estimate MomentumAzurRx BioPharma, Inc. Estimate Momentum
www.nasdaq.com - March 18 at 6:23 PM
AzurRx up 20% premarket on positive MS1819 dataAzurRx up 20% premarket on positive MS1819 data
seekingalpha.com - March 18 at 9:25 AM
AzurRx BioPharma Announces Presentation on Its Positive Phase II Data in MS1819-SD in Chronic Pancreatitis at the 2019 Digestive Disease Week ConferenceAzurRx BioPharma Announces Presentation on Its Positive Phase II Data in MS1819-SD in Chronic Pancreatitis at the 2019 Digestive Disease Week Conference
finance.yahoo.com - March 18 at 9:25 AM
AzurRx BioPharma to Present at the 2019 Annual Roth Capital Conference (March 19) and the Oppenheimer 29th Annual Healthcare Conference (March 20)AzurRx BioPharma to Present at the 2019 Annual Roth Capital Conference (March 19) and the Oppenheimer 29th Annual Healthcare Conference (March 20)
finance.yahoo.com - March 15 at 10:08 AM
AzurRx BioPharma Announces Poster Presentation at the Americas Hepato-Pancreato-Biliary Association 2019 Annual MeetingAzurRx BioPharma Announces Poster Presentation at the Americas Hepato-Pancreato-Biliary Association 2019 Annual Meeting
finance.yahoo.com - March 12 at 11:00 AM
Form 8-K AzurRx BioPharma, Inc. For: Feb 14 - StreetInsider.comForm 8-K AzurRx BioPharma, Inc. For: Feb 14 - StreetInsider.com
www.streetinsider.com - February 22 at 5:52 PM
AzurRx up 30% on start of mid-stage study of MS1819-SDAzurRx up 30% on start of mid-stage study of MS1819-SD
seekingalpha.com - February 20 at 5:42 PM
AzurRx BioPharma Announces First Patients Dosed in Phase II OPTION Clinical TrialAzurRx BioPharma Announces First Patients Dosed in Phase II OPTION Clinical Trial
finance.yahoo.com - February 20 at 10:00 AM
What Kind Of Shareholder Owns Most AzurRx BioPharma, Inc. (NASDAQ:AZRX) Stock?What Kind Of Shareholder Owns Most AzurRx BioPharma, Inc. (NASDAQ:AZRX) Stock?
finance.yahoo.com - January 21 at 4:57 PM
AzurRx BioPharma Announces Initiation of Phase II OPTION Clinical Trial of MS1819-SD in Cystic Fibrosis PatientsAzurRx BioPharma Announces Initiation of Phase II OPTION Clinical Trial of MS1819-SD in Cystic Fibrosis Patients
finance.yahoo.com - December 19 at 9:41 AM
AzurRx Biopharma to acquire payment rights to MS1819-SD from Protea BiosciencesAzurRx Biopharma to acquire payment rights to MS1819-SD from Protea Biosciences
seekingalpha.com - December 12 at 4:59 PM
AzurRx BioPharma (AZRX) to Acquire Payment Rights to Lead Drug Candidate MS1819-SD from Protea Biosciences GroupAzurRx BioPharma (AZRX) to Acquire Payment Rights to Lead Drug Candidate MS1819-SD from Protea Biosciences Group
www.streetinsider.com - December 12 at 4:59 PM
AzurRx BioPharma to Acquire Payment Rights to Lead Drug Candidate MS1819-SD from Protea Biosciences GroupAzurRx BioPharma to Acquire Payment Rights to Lead Drug Candidate MS1819-SD from Protea Biosciences Group
finance.yahoo.com - December 12 at 4:59 PM
AZRX: 3Q:18 Financial and Operational SummaryAZRX: 3Q:18 Financial and Operational Summary
finance.yahoo.com - December 4 at 4:39 PM
AzurRx BioPharma to Present at Upcoming Investor ConferencesAzurRx BioPharma to Present at Upcoming Investor Conferences
finance.yahoo.com - December 4 at 9:40 AM
AzurRx BioPharma to Present at the 11th Annual LD Micro Main EventAzurRx BioPharma to Present at the 11th Annual LD Micro Main Event
www.baystreet.ca - November 28 at 9:50 AM
AzurRx BioPharma Receives Sanction of Cystic Fibrosis Therapeutics Development Network for the Study of MS1819-SD in CF Patients with EPIAzurRx BioPharma Receives Sanction of Cystic Fibrosis Therapeutics Development Network for the Study of MS1819-SD in CF Patients with EPI
finance.yahoo.com - November 1 at 9:14 AM
AzurRx BioPharma (AZRX) Announces FDA Acceptance of IND Application for Phase 2 Clinical Trial of MS1819-SDAzurRx BioPharma (AZRX) Announces FDA Acceptance of IND Application for Phase 2 Clinical Trial of MS1819-SD
www.streetinsider.com - October 17 at 9:25 AM
FDA signs off on mid-stage study of AzurRx Bios lead candidate MS1819-SD; shares up 2%FDA signs off on mid-stage study of AzurRx Bio's lead candidate MS1819-SD; shares up 2%
seekingalpha.com - October 16 at 4:13 PM
AzurRx BioPharma Announces FDA Acceptance of IND Application for Phase 2 Clinical Trial of MS1819-SD in Patients with Exocrine Pancreatic Insufficiency Due to Cystic FibrosisAzurRx BioPharma Announces FDA Acceptance of IND Application for Phase 2 Clinical Trial of MS1819-SD in Patients with Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
finance.yahoo.com - October 16 at 9:21 AM
Data reaffirms positive safety profile with no severe adverse eventsData reaffirms positive safety profile with no severe adverse events
globenewswire.com - September 25 at 9:28 AM
AZRX: Final Results from Phase II EPI TrialAZRX: Final Results from Phase II EPI Trial
finance.yahoo.com - September 24 at 4:16 PM
AzurRx Bios MS1819-SD successful in mid-stage EPI study; shares ahead 26% premarketAzurRx Bio's MS1819-SD successful in mid-stage EPI study; shares ahead 26% premarket
seekingalpha.com - September 24 at 9:32 AM
AzurRx BioPharma Announces Positive Outcome with MS1819-SD Showing Statistically Significant Efficacy in a Phase IIa Exocrine Pancreatic Insufficiency Trial in Chronic PancreatitisAzurRx BioPharma Announces Positive Outcome with MS1819-SD Showing Statistically Significant Efficacy in a Phase IIa Exocrine Pancreatic Insufficiency Trial in Chronic Pancreatitis
finance.yahoo.com - September 24 at 9:32 AM
AZRX: Phase 2 Cystic Fibrosis Study to StartAZRX: Phase 2 Cystic Fibrosis Study to Start
finance.yahoo.com - August 28 at 4:12 PM
AzurRx BioPharma to Present at the Rodman & Renshaw 20th Annual Global Investment Conference on September 5thAzurRx BioPharma to Present at the Rodman & Renshaw 20th Annual Global Investment Conference on September 5th
finance.yahoo.com - August 28 at 9:30 AM
AzurRx BioPharma to Present at the 2018 Cannacord Genuity 38th Annual Growth Conference (August 9th)AzurRx BioPharma to Present at the 2018 Cannacord Genuity 38th Annual Growth Conference (August 9th)
finance.yahoo.com - August 1 at 11:19 AM
AZRX: AzurRx Announces Completion of Phase 2a MS1819 TrialAZRX: AzurRx Announces Completion of Phase 2a MS1819 Trial
finance.yahoo.com - July 2 at 4:04 PM
AzurRx BioPharma Announces Successful Phase IIa Trial of MS1819-SD in Exocrine Pancreatic InsufficiencyAzurRx BioPharma Announces Successful Phase IIa Trial of MS1819-SD in Exocrine Pancreatic Insufficiency
finance.yahoo.com - June 30 at 11:59 AM
AzurRx appoints Dr. James Pennington as Chief Medical OfficerAzurRx appoints Dr. James Pennington as Chief Medical Officer
seekingalpha.com - May 30 at 9:40 AM
This page was last updated on 7/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel